Roche pays $190M upfront for Hanmi's muscle-sparing obesity drug
Roche has agreed to pay $190 million upfront to license a non-incretin obesity treatment from South Korea's Hanmi Pharm, with milestone payments potentially reaching $2.3 billion. The deal extends Roche's recent pattern of acquiring obesity-related assets through partnerships. The candidate is still in early-stage development and aims to preserve muscle mass while promoting weight loss.
Roche’s latest licensing agreement with Hanmi Pharm centers on an experimental obesity drug that differs from the incretin-based therapies dominating the market. The candidate, still in early-stage trials, is designed to reduce weight while specifically preserving muscle mass—a key concern for patients using existing treatments. The deal includes an upfront payment of $190 million, with potential milestone payments up to $2.3 billion, reflecting Roche’s continued push into obesity care through partnerships rather than internal development alone. This move follows a series of similar acquisitions by the Swiss pharma giant.
This deal could reshape obesity treatment options by addressing muscle loss, a side effect that affects long-term health and quality of life. Patients may benefit from therapies that offer safer weight reduction, while healthcare systems could see reduced costs from fewer muscle-related complications. However, early-stage candidates carry uncertainty, and the high financial stakes may pressure pricing if approved. The agreement also signals growing competition among major drugmakers, potentially accelerating innovation but also raising questions about equitable access to new treatments.